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Human cytomegalovirus (HCMV) was recently shown to encode a large number of spliced mRNAs. While
the nuclear export of unspliced viral transcripts has been extensively studied, the role of host mRNA
export factors in HCMV mRNA trafﬁcking remains poorly deﬁned. We found that the eIF4AIII RNA
helicase, a component of the exon junction complex, was necessary for efﬁcient virus replication.
Depletion of eIF4AIII limited viral DNA accumulation, export of viral mRNAs from the nucleus, and the
production of progeny virus. However eIF4AIII was dispensable for the association of viral transcripts
with ribosomes. We found that pateamine A, a natural compound that inhibits both eIF4AI/II and
eIF4AIII, has potent antiviral activity and inhibits HCMV replication throughout the virus lytic cycle. Our
results demonstrate that eIF4AIII is required for efﬁcient HCMV replication, and suggest that eIF4A family
helicases may be a new class of targets for the development of host-directed antiviral therapeutics.
& 2016 Published by Elsevier Inc.Introduction
Post-transcriptional control of gene expression is a highly
regulated process in mammalian cells. Following transcription pri-
mary transcripts undergo substantial remodeling in the nucleus. A
multi-component complex termed the spliceosome recognizes and
removes introns from primary mRNAs (Jurica and Moore, 2003).
Concomitant with splicing, RNA binding proteins are deposited on
the mRNA and signal that the mRNA is mature and ready for export
to the cytoplasm. The mature, spliced mRNA then transits through
the nuclear pore to the cytoplasmwhere it is translated into protein
(Dreyfuss et al., 2002). Each step in this process requires a distinct
complement of protein complexes and is regulated in response to
environmental cues (Chang et al., 2013). The coordinated actions of
the splicing machinery and subsequent RNA binding proteins
ensure that only fully mature mRNAs are released to the cytoplasm
for translation into protein (Wang and Burge, 2008; Parsyan et al.,
2011).
Splicing was traditionally thought to have a limited role in
expanding the complexity of herpesvirus proteomes. However,
several recent studies have revealed extensive splicing of herpes-
virus transcriptomes (Gatherer et al., 2011; Stern-Ginossar et al.,
2012). Human cytomegalovirus (HCMV) encodes at least 132
spliced mRNAs (Gatherer et al., 2011), and many HCMV transcriptsorman).undergo alternative splicing. The widespread post-transcriptional
processing of viral mRNAs likely accounts for part of the surpris-
ingly complex HCMV proteome (Stern-Ginossar et al., 2012). In
addition, these data suggest that host factors required for the
transport of spliced mRNAs may play important roles in HCMV
replication.
One host factor involved in the export of spliced mRNAs from
the nucleus is the eIF4AIII RNA helicase. Interactions between
eIF4AIII and the spliceosome result in eIF4AIII deposition on
spliced mRNAs proximal to newly ligated exon junctions, although
eIF4AIII is not an essential component of the spliceosome (Fer-
raiuolo et al., 2004; Shibuya et al., 2004; Shiimori et al., 2013).
While eIF4AIII itself has no RNA binding speciﬁcity, two associated
proteins, Y14 and magoh, coordinate eIF4AIII deposition adjacent
to splice junctions (Bono and Gehring, 2011). Together with the
barentsz protein, eIF4AIII, Y14, and magoh comprise the core
proteins of the exon junction complex, or EJC (Palacios et al.,
2004). After nucleation on splice junctions, the EJC core promotes
the recruitment of additional proteins that facilitate nuclear export
of spliced mRNAs (Bono and Gehring, 2011).
eIF4AIII also contributes to mRNA quality control and translation
in the cytoplasm. Mature mRNAs are exported from the nucleus
bound by the cap binding complex (CBC). In the cytoplasm, the CBC
promotes the initial, or pioneer, round of translation during which
bound EJCs are removed from the mRNA. Failure to remove EJCs
targets the mRNA for degradation through the nonsense-mediated
decay pathway (Alexandrov et al., 2012; Chang et al., 2007). In
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eIF4AIII helicase activity resolves secondary structure in the 50
untranslated region (50UTR) that otherwise impedes ribosome
scanning. While the CBC facilitates the translation of some viral
mRNAs (Sharma et al., 2012), the potential role of eIF4AIII in viral
protein synthesis has not been determined.
In this study we found that the host eIF4AIII protein is required
for efﬁcient HCMV replication. Depletion of eIF4AIII decreased
viral DNA replication, the expression of late transcripts, and lim-
ited the production of progeny virus. We found that depletion of
eIF4AIII limits the cytoplasmic accumulation of HCMV mRNAs,
suggesting a role for eIF4AIII in the nuclear export of viral tran-
scripts. HCMV transcripts efﬁciently associate with polysomes in
eIF4AIII-depleted cells, suggesting that eIF4AIII is not required for
the translation of viral mRNAs. Based on the requirement for
eIF4AIII for efﬁcient virus replication and our previous work
showing that inhibiting the related eIF4AI/II helicases decreased
virus replication, we tested if pateamine A, a bioavailable natural
compound that inhibits all three eIF4A family members, had
antiviral activity against HCMV. We found that pateamine A
potently inhibited HCMV replication during all stages of the virus
lytic cycle at doses that did not affect the viability of uninfected
cells. Together our results demonstrate that eIF4AIII is required for
efﬁcient HCMV replication, and suggest that eIF4A family helicases
may be a new class of targets for the development of host-directed
antiviral therapeutics.Results
eIF4AIII is required for efﬁcient HCMV replication
To determine if eIF4AIII is required for HCMV replication, we
measured HCMV replication in eIF4AIII-depleted cells. Conﬂuent
ﬁbroblasts were transduced with lentivirus expressing eIF4AIII-
speciﬁc shRNAs (Fig. 1A), and the production of cell free virus in
the supernatant was measured over a single round of viral repli-
cation. eIF4AIII depletion resulted in a greater than 150 fold defect
in virus production at all times measured as compared to control
cells expressing a scrambled shRNA with no predicted targets
(Fig. 1B). Similar results were obtained in cells expressing a second
eF4AIII-speciﬁc shRNA (Fig. S1). We conclude that eIF4AIII is
required for efﬁcient HCMV replication.
To determine where the block in virus replication occurred in
eIF4AIII-depleted cells, we measured the expression of repre-
sentative immediate early (IE), early, and late proteins throughout
a time course of infection. The IE protein IE1 was efﬁciently
expressed in control and eIF4AIII depleted cells at all times afterFig. 1. eIF4AIII is required for efﬁcient HCMV replication. (A) Primary human ﬁbroblasts
(sh4A3) shRNA and then infected with HCMV (MOI of 3). (A) Representative Western blo
free supernatants were harvested at the indicated time and quantiﬁed by the TCID50 m
*po0.05; **po0.01).infection (Fig. 2A). In contrast the expression of the HCMV early
protein pUL44 was reduced and the HCMV late protein pp28 was
signiﬁcantly diminished in eIF4AIII depleted cells.
The HCMV pUL44 gene is required for viral DNA accumulation
(Pari et al., 1993); therefore the reduced pUL44 levels in eIF4AIII-
depleted cells suggested that eIF4AIII was necessary for efﬁcient
viral DNA replication. Control or eIF4AIII-depleted cells were
infected with HCMV, and viral DNA accumulation was measured
by qPCR. As a positive control, infected cells were treated with
phosphonoacetic acid (PAA), a chemical inhibitor of the viral
polymerase (Huang, 1975). Depletion of eIF4AIII reduced viral DNA
accumulation over 40 fold as compared to control cells (Fig. 2B).
We conclude that eIF4AIII is required for efﬁcient HCMV DNA
accumulation.
HCMV late gene transcription requires viral DNA replication.
Therefore the defect in viral DNA accumulation in eIF4AIII-
depleted cells suggested that late gene transcription would be
decreased. Consistent with the defect in viral DNA replication,
depletion of eIF4AIII diminished transcription of the HCMV late
gene UL99, which encodes the pp28 protein, by ﬁvefold (Fig. 2C).
Thus eIF4AIII is required for efﬁcient transcription of an HCMV late
transcript, likely due to the requirement for eIF4AIII for efﬁcient
early gene expression and viral DNA replication.
eIF4AIII is required for efﬁcient nuclear export of viral transcripts
As a core component of the EJC, eIF4AIII facilitates the export of
spliced transcripts from the nucleus to the cytoplasm (Singh and
Lykke-Andersen, 2003). To determine if eIF4AIII facilitates the
export of HCMV mRNAs, we measured the nuclear to cytoplasmic
ratio of viral mRNAs in eIF4AIII-depleted cells. Control or eIF4AIII-
depleted cells were infected with HCMV and fractionated into
nuclear and cytoplasmic fractions. The purity of the cytoplasmic
and nuclear fractions was monitored by Western blot using anti-
bodies speciﬁc for tubulin and lamin A/C, respectively (Fig. 3A).
The decrease in tubulin loading was not consistently observed. The
nuclear to cytoplasmic ratio of representative IE, early, and late
viral mRNAs was then measured by qRT-PCR. This approach
measures the relative distribution of an mRNA between the two
compartments, and is independent of the total abundance of the
transcript. eIF4AIII depletion reduced the accumulation of each
viral mRNA in the cytoplasm by 50% as compared to control cells.
Interestingly eIF4AIII depletion inhibited the cytoplasmic accu-
mulation of both spliced (IE1) and unspliced (UL44 and UL99) viral
mRNAs (Fig. 3B). We conclude that eIF4AIII is necessary for the
efﬁcient accumulation of HCMV transcripts in the cytoplasm dur-
ing infection, suggesting a role for eIF4AIII in the nuclear export of
viral mRNAs.were transduced with lentiviruses expressing a scrambled (scr) or eIF4AIII-speciﬁc
t demonstrating reduced eIF4AIII protein expression at 72 h postinfection. (B) Cell-
ethod (closed bars¼scrambled shRNA, open bars¼eIF4AIII-speciﬁc shRNA; n¼3;
Fig. 2. Characterization of the HCMV lytic cycle in eIF4AIII-depleted cells. (A) Cells were transduced and infected as in Fig. 1. Protein expression was measured by Western
blot (n¼3). (B) Cells were transduced as in Fig. 1 and then infected with HCMV at a multiplicity of 0.05. Viral DNA was quantiﬁed at 96 h after infection by quantitative real-
time PCR (n¼3; ﬁlled bars¼untreated, open bars¼PAA treated). (C) Cells were transduced and infected as in Fig. 1 and the relative abundance of the UL99 transcript in total
RNA was measured at 72 h after infection by quantitative reverse transcriptase real-time PCR (qRT-PCR). The abundance of the UL99 transcript in the scrambled control is set
to one (n¼3). For all panels, *po0.05; **po0.01.
Fig. 3. eIF4AIII is necessary for efﬁcient accumulation of HCMV mRNAs in the cytoplasm of infected cells. (A) Cells were transduced and infected as in Fig. 1. Seventy two
hours after infection the cells were fractionated into nuclear and cytosolic fractions, and the purity of the fractions determined by Western blot using antibodies speciﬁc for
the cytosolic protein tubulin, and the nuclear protein lamin A/C. (B) As in A, except the cytoplasmic to nuclear ratio of each RNA was determined by qRT-PCR as described in
“Materials and methods”. The ratio in control cells was set to one (n¼3; *po0.05).
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eIF4AIII also stimulates mRNA translation in the cytoplasm
during the pioneer round of translation (Hwang et al., 2010; Le Hir
and Seraphin, 2008). To determine if eIF4AIII is required for
translation of HCMV mRNAs, we measured the effect of eIF4AIII
depletion on the association of cytoplasmic viral mRNAs with
polysomes. mRNAs that are actively undergoing translation are
bound by multiple ribosomes, or polysomes, which can be sepa-
rated from single ribosomes and ribosomal subunits by cen-
trifugation through linear sucrose gradients. The extent to which
an mRNA is being translated can be inferred from the distribution
of the mRNA throughout the sucrose gradient. Importantly, only
cytoplasmic mRNAs are analyzed in this assay, allowing us to
separate the effect of eIF4AIII on viral mRNA expression and
nuclear export from its role in the translation of viral mRNAs.
We ﬁrst determined if depleting cells of eIF4AIII affected
polysome abundance in HCMV infected cells. Cytoplasmic extracts
of infected control or eIF4AIII-depleted cells were resolved
through linear sucrose density gradients and the distribution of
ribosomal RNA (rRNA) throughout the gradient was determined by
gel electrophoresis as previously described. Fig. 4A shows that
polysomes were present in eIF4AIII-depleted cells, and that qua-
litatively polysome abundance appeared slightly reduced in the
absence of eIF4AIII. These results are consistent with previous
studies showing that eIF4AIII depletion does not result in an
overall decrease in protein synthesis (Choe et al., 2014).
We next determined the effect of eIF4AIII depletion on the
translation of speciﬁc HCMV mRNAs by measuring their distribu-
tion throughout the sucrose gradient by qRT-PCR. While weobserved a slight increase in the amount of the IE1 mRNA in the
fractions containing monosomes (Fig. 4B, fractions 5–7), the dif-
ference between control and eIF4AIII-depleted cells was not sta-
tistically signiﬁcant. Similarly the abundance of IE1 mRNA in the
fractions containing heavier polysomes (fractions 11–14) was
unchanged. The distribution of cytosolic UL99 mRNA in the
sucrose gradient was also similar in control and eIF4AIII-depleted
cells (Fig. 4C). These results suggest that eIF4AIII is not required for
the efﬁcient association of viral mRNAs with ribosomes in the
cytoplasm.
To ensure that the migration of the viral mRNAs in the gradient
reﬂected their association with polysomes rather than a potential
interaction with HCMV virions, we determined if EDTA treatment
altered the migration of the viral mRNA in the gradient. EDTA
chelates magnesium cations that are required to maintain ribo-
some integrity (Arnstein et al., 1965). EDTA treatment shifted both
ribosomal RNAs and viral mRNAs to the lighter fractions (Fig. S2),
demonstrating that the migration pattern of viral mRNAs in the
sucrose gradient reﬂected their association with ribosomes.
Pateamine A, a natural product inhibitor of eIF4A helicases, has
potent antiviral properties
We previously found that treating HCMV-infected cells with
hippuristanol, a small molecule inhibitor of the eIF4AI/II helicases
inhibited HCMV replication (Lenarcic et al., 2014). Our current data
suggested that eIF4AIII is also important for virus replication. We
therefore reasoned that an inhibitor of all three eIF4A family
members might signiﬁcantly impair virus growth. One such inhi-
bitor is the natural product pateamine A (Bordeleau et al., 2006;
Fig. 4. eIF4AIII is not required for efﬁcient association of HCMV mRNAs with polysomes. (A) Cells were transduced and infected as in Fig. 1. Seventy two hours after infection
cytosolic extracts were resolved through 10–50% linear sucrose gradients. The presence of ribosomal RNAs (28S, 18S) in each fraction was monitored by agarose gel
electrophoresis. Monosomes were present in fractions 5–7, while heavy polysomes were present in fractions 10–14. (B and C) As in A, except the abundance of the indicated
viral mRNAs in each gradient fraction was determined by qRT-PCR (n¼3; closed bars¼scrambled; open bars¼eIF4AIII depleted cells).
Fig. 5. Pateamine A inhibits HCMV replication in a dose dependent manner. (A) Uninfected cells were treated with the indicated concentrations of pateamine A (PatA), and
toxicity was measured by the lactate dehydrogenase (LDH) assay 120 h later. The results are representative of at least three experiments. (B) Cells were infected as in Fig. 1,
and treated with the indicated concentrations of PatA at the time of infection. The amount of cell free virus in the supernatants was quantiﬁed at 120 h after infection by the
TCID50 method (n ¼3; ***po0.001). (C) Cells were infected as in Fig. 1, and treated with PatA (100 nM) at the time of infection. The amount of cell free virus in the
supernatants was determined by the TCID50 method (closed bars ¼vehicle, open bars¼PatA; n¼3; dashed line indicates limit of detection).
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inhibits all three eIF4A helicases (Bordeleau et al., 2005; Korneeva,
2007; Kuznetsov et al., 2009; Low et al., 2007a). Importantly,
pateamine A is minimally toxic to quiescent cells, bioavailable and
well-tolerated in vivo for extended periods (Di Marco et al., 2012;
Kuznetsov et al., 2009). A complete synthesis reaction has been
developed for pateamine A, resulting in a stabilized derivative,
des-methyl, des-amino pateamine A (Kuznetsov et al., 2009)
(DMDA-PatA; further referred to as PatA). We therefore deter-
mined if PatA has antiviral properties in addition to its proven
efﬁcacy as a chemotherapeutic agent (Lenarcic et al., 2014).
We ﬁrst determined if PatA was toxic to primary ﬁbroblasts.
Concentrations of PatA up to and including 100 nM did not induce
cytotoxicity over 120 h (Fig. 5A). We next determined the effect of
PatA treatment on HCMV replication in an endpoint assay. Dif-
ferent concentrations of PatA were added at the time of infection,
and the levels of cell free virus were measured 120 h later. Whilethe IC50 of PatA was not precisely determined, concentrations of
PatA as low as 10 nM limited HCMV replication (Fig. 5B), and no
cell free virus was observed at a concentrations of 100 nM. We also
measured the effect of 100 nM PatA treatment throughout a single
virus replication cycle. When PatA was added at the time of
infection, the levels of cell free virus remained below the limit of
detection at all times after infection (Fig. 5C). We conclude that
PatA inhibits HCMV replication in a dose-dependent manner at
concentrations that are not toxic to uninfected cells.
To determine where in the viral life cycle PatA inhibited HCMV
replication we examined the effects of PatA on viral protein
expression over a single viral replication cycle. 100 nM PatA added
at the time of infection reduced the expression of the IE1 protein
at 24 h after infection, and IE1 levels remained reduced through-
out the time course of infection (Fig. 6A). PatA also delayed and
reduced the accumulation of an HCMV early (pUL44) and late
Fig. 6. Pateamine A inhibits HCMV replication. (A) Cells were infected at a multiplicity of three in the presence of 100 nM PatA. Viral protein expression was measured at the
indicated times by Western blot. (B) Cells were infected with HCMV at a multiplicity of 0.05 and treated as in A. Viral DNA was quantiﬁed at 96 h after infection by
quantitative real-time PCR (n¼3).
Fig. 7. Pateamine A inhibits HCMV replication throughout the virus lytic cycle. Cells were infected with HCMV (MOI of 3) and then treated with PatA (100 nM) for the
indicated 24 h period. Vehicle treated cells were harvested at the beginning and end of drug treatment as controls. (A) The accumulation of the indicated viral proteins
during PatA treatment was measured by Western blot. (B) Cells were infected and treated as in A, and free virus in the supernatants was quantiﬁed by the TCID50 method
(closed bars¼vehicle control, open bars¼PatA; n¼3).
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expression PatA inhibited viral DNA accumulation (Fig. 6B).
We next measured the effect of PatA on viral protein accumu-
lation when added to cells after infection had already been
established. Cells were ﬁrst infected with HCMV, and PatA was
added at the different times after infection for a twenty-four hour
period. Untreated controls were harvested at the beginning and
end of each treatment window. The addition of PatA at any time
after infection prevented further increase in the abundance of viral
proteins (Fig. 7A). For example, the HCMV late protein pp28 was
ﬁrst detected at low levels at 48 h after infection in untreated cells.
While pp28 levels increased between 48 and 72 h in untreated
cells, the addition of PatA at 48 h prevented further accumulation
of pp28 protein. Similar results were observed for the HCMV early
protein pUL44. PatA did not limit IE1 expression later in infection
likely due to the long half-life of the IE1 protein (Teng et al., 2012)
rather than the continued synthesis of IE1 in the presence of PatA.
We also found that adding PatA at any time after infection
prevented further accumulation of cell free virus (Fig. 7B). Virus
was ﬁrst detected in the supernatant of untreated samples at 72 h
after infection. In untreated cells, the amount of cell free virus
increased 50 fold between 72 and 96 h. When PatA was added at
72 h, there was no increase in virus production over the twenty
four hour period. Similar results were found when PatA was added
from 96 to 120 h after infection. We conclude that PatA is capable
of inhibiting HCMV replication during any stage of the lytic cycle.Discussion
Our results show that the eIF4AIII RNA helicase is required for
progression from the immediate early to early stage of the HCMV
lytic cycle and for the efﬁcient production of progeny virus. The
defect in virus replication in eIF4AIII-depleted cells correlates with
our ﬁnding that eIF4AIII is required for the efﬁcient export of viral
mRNAs from the nucleus. However we ﬁnd that eIF4AIII is dis-
pensable for the association of viral mRNAs with ribosomes in the
cytoplasm. Building on our previous results showing that inhibi-
tors of eIF4AI/II can limit HCMV replication, we found that a
chemical inhibitor of all three eIF4A family helicases, pateamine A,
potently inhibited HCMV replication at doses that were not toxic
to uninfected cells. Importantly, PatA inhibited viral protein
synthesis and the further production of progeny virus at any stage
of infection. Our results therefore identify eIF4AIII as a novel target
for the development of new host-directed antiviral therapeutics.
As a core component of the EJC, eIF4AIII facilitates the export of
spliced host mRNAs from the nucleus. Our data shows that eIF4AIII
is also required for the efﬁcient nuclear export of HCMV mRNAs, as
eIF4AIII depletion reduced the levels of viral mRNAs in the cyto-
plasm (Fig. 3). This may reﬂect a requirement for the EJC in the
nuclear export of viral mRNAs. Interestingly, the EJC accessory
protein UAP56 binds to the HCMV UL69 protein (pUL69) and
facilitates the nuclear export of unspliced viral mRNAs (Gatﬁeld et
al., 2001; Zielke et al., 2012). Perhaps pUL69 acts in concert with
the EJC to trafﬁc HCMV mRNAs to the cytoplasm. Such an
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for efﬁcient nuclear export of both spliced and unspliced viral
transcripts. Alternatively, HCMV could utilize eIF4AIII an EJC-
independent mRNA export pathway. However our results cannot
exclude the possibility that eIF4AIII is necessary for the expression
a short-lived viral or cellular protein needed to trafﬁc HCMV
mRNAs. Future studies examining the role of additional EJC pro-
teins and their potential interactions with viral factors will be
needed to discriminate between these possible roles.
We found eIF4AIII depletion resulted in a greater than 100 fold
defect in virus replication. How might eIF4AIII facilitate virus
replication? eIF4AIII depletion decreased the cytoplasmic accu-
mulation of the IE1 mRNA (Fig. 3B) but did not signiﬁcantly impact
IE1 protein levels. This likely reﬂects the high level of transcription
of the IE1 mRNA and the long half-life of the IE1 protein, which
together allow for efﬁcient IE1 protein expression despite the
reduction in cytosolic IE1 transcript. eIF4AIII depletion also
reduced nuclear export of the UL44 early transcript and decreased
UL44 protein (pUL44) levels (Fig. 2A), likely explaining the reduced
viral DNA accumulation (Fig. 2B) in eIF4AIII-depleted cells. Con-
sistent with the defect in viral DNA replication, eIF4AIII depletion
reduced the abundance of the UL99 late transcript (Fig. 2C) and
further limited the accumulation of UL99 transcripts in the cyto-
plasm. Together our results suggest a model where eIF4AIII is
required for transition from the immediate early to early stage of
infection. The reduction in early protein synthesis when eIF4AIII is
depleted limits viral DNA replication resulting in decreased
expression of viral late transcripts, which also require eIF4AIII for
their efﬁcient nuclear export. Thus our results suggest a model
where the defect in the nuclear export of viral mRNAs in eIF4AIII-
depleted cells results in a cascading effect, which culminates in
greatly reduced late protein expression and infectious virus pro-
duction. However it is important to note that eIF4AIII could also be
required for the expression of unknown host or viral factors nee-
ded for HCMV replication.
We also found that while eIF4AIII depletion limited HCMV
mRNA nuclear export, the remaining viral RNAs that reached the
cytoplasm in eIF4AIII-depleted cells efﬁciently associated with
polysomes. This suggests that that eIF4AIII is not required for the
efﬁcient translation of viral mRNAs (Fig. 4). Together with the CBC,
eIF4AIII stimulates mRNA translation during the pioneer round of
translation (Lejeune et al., 2002). While the role of the pioneer
round in HCMV protein synthesis has not been tested, our data
suggest that if HCMV mRNAs utilize a pioneer round of translation,
eIF4AIII is not required for this process.
Based on our previous work showing eIFAI/II inhibition or
depletion limited HCMV replication and our current data demon-
strating a requirement for eIF4AIII, we determined if pateamine A
(PatA), a biologically available inhibitor of all three eIF4A helicases,
might have antiviral properties. We found that PatA decreased
HCMV replication below the limit of detection when present from
the start of infection at concentrations that were not toxic to
uninfected cells. We previously showed that the eIF4AI/II inhibitor
hippuristanol potently inhibited HCMV replication when added at
the time of infection, but virus replication became resistant to
hippuristanol during the late stage of infection. In contrast PatA
inhibited HCMV replication during any stage of the virus lytic cycle.
Together these results suggest that the inhibition of HCMV repli-
cation by PatA is likely due to the combined inhibition all three
members of the eIF4A helicase family. PatA likely suppresses virus
replication by inhibiting multiple eIF4AI/II- and eIF4AIII-dependent
steps in the virus replicative cycle, resulting in a profound defect in
HCMV replication and viral protein expression.
Our results raise the possibility that PatA or similar drugs might
be useful as antiviral drugs. PatA is an effective in vivo che-
motherapeutic (Kuznetsov et al., 2009), prevents cachexia (DiMarco et al., 2012) in small animal models, and is well-tolerated in
mice for extended periods of time (Kuznetsov et al., 2009). This
suggests that PatA might be useful in vivo to limit HCMV disease. In
addition we ﬁnd that PatA has antiviral activity against diverse RNA
and DNA viruses, suggesting a potential use for PatA as a broad
spectrum antiviral (Ziehr and Moorman, unpublished observation).
Our results therefore expand the potential uses for PatA or similar
eIF4A family inhibitors to the treatment of viral disease.Materials and methods
Cells, viruses, and reagents
Primary human foreskin ﬁbroblasts (HFFs) were grown in
DMEM containing 10% newborn calf serum. Cells were used
between passage 5 and 15 in all experiments. Replication defective
lentiviruses expressing eIF4AIII-speciﬁc shRNAs (TRCN 0000061855
or 0000061856) were generated as described previously (Lenarcic
et al., 2014). HFFs were transduced with lentivirus overnight in the
presence of polybrene (4 μg/ml). The next day the media was
replaced with serum free DMEM, and the cells were used for
experiments at 72 h after transduction. Efﬁcient eIF4AIII depletion
was routinely assessed by quantitative real-time PCR (qRT-PCR) or
Western blot.
A variant of the HCMV AD169 strain containing a green ﬂuor-
escent protein expression cassette driven by the SV40 promoter
(ADGFP; Wang et al., 2004) was used as the wild type virus strain
in all studies. Unless otherwise noted, all infections were per-
formed at a multiplicity of infection (MOI) of three in a minimal
volume of serum free media. Infected cells were harvested by
scraping and stored at 80 °C until analyzed. Quantiﬁcation of
cell-free virus by the TCID50 method was performed as described
previously (Moorman and Shenk, 2010).
DMDA-pateamine A (PatA) (Kuznetsov et al., 2009), a synthetic
analogue of pateamine A, was generously provided by Dr. Daniel
Romo (Texas A&M University).
Preparation of nuclear and cytosolic fractions
Infected cells were harvested by scraping, pelleting, and re-
suspending in fractionation buffer (20 mM Tris–HCl, pH 7.4,
140 mM KCl, 5mM MgCl2, 1% Triton-X 100, 10 mM DTT). The lysate
was passed ﬁve times through a 27 gauge needle, and then cen-
trifuged at 1150 g for ﬁve minutes. The resulting supernatant
contained the cytosolic fraction, while the pellet contained the
nuclear fraction. A portion of each fraction was analyzed by
Western blot using antibodies speciﬁc for tubulin or lamin A/C to
monitor the purity of the cytoplasmic and nuclear fractions,
respectively.
Analysis of polysomes and polysome-associated mRNAs
Polysome isolation and analysis were performed as described
previously (Lenarcic et al., 2014). Brieﬂy, cells were treated with
cycloheximide (CHX; 100 μg/ml) in media for ten minutes, washed
twice in PBS containing CHX, and collected by scraping. The cells
were pelleted by centrifugation at 5000 g for ten minutes, and
then resuspended in 1 ml of polysome lysis buffer (20 mM Tris–
HCl, pH 7.4, 140 mM KCl, 5mM MgCl2, 1% Triton-X 100, 10 mM
DTT) containing CHX. Cells were incubated on ice for ten minutes
and then disrupted by ﬁve passages through a 27 gauge needle.
Nuclei were removed by centrifugation for ﬁve minutes at
1150 g. The supernatant was cleared of mitochondria by cen-
trifugation at 21,000 g for ten minutes, and then layered onto a
10–50% linear sucrose gradient (made in polysome lysis buffer)
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4 °C in a SW41 swinging bucket rotor at 35,000 rpmwith no brake.
After centrifugation the gradients were manually fractionated
from the top of the gradient into 750 μl fractions. RNA was
extracted from a portion of each gradient fraction and ribosomal
RNA (rRNA) was visualized on 2% agarose gels.
For quantiﬁcation of viral mRNAs in each fraction of the sucrose
gradient, total RNA was extracted with Trizol from an equal
volume of each gradient fraction. The RNA was then treated with
DNase (Ambion), and reverse transcribed to cDNA as described
below. The abundance of the speciﬁed mRNA in each gradient
fraction was quantiﬁed by qRT-PCR by comparison to a standard
curve as described previously (Terhune et al., 2010). The amount of
the RNA in all fractions was then summed to determine the total
copies present in the gradient. The amount of the RNA in each
fraction is shown as the percentage of the total copies present in
the entire gradient.
Quantiﬁcation of nucleic acids and proteins
DNase-treated RNA was isolated as above, and reverse tran-
scribed using the High Capacity cDNA Reverse Transcription Kit
(Life Technologies). qRT-PCR was performed on a Roche LC480
using SYBR Green master mix and primers speciﬁc for the indi-
cated mRNA as described previously (Ziehr et al., 2015).
To quantify viral DNA accumulation, DNA was extracted from
infected cells by phenol:chloroform extraction as described pre-
viously (Moorman and Shenk, 2010). Brieﬂy, 500 ng of DNA were
analyzed by quantitative real-time PCR (qPCR) using primers
speciﬁc for the HCMV major immediate early promoter. The
abundance of viral DNA was determined by comparison to a
standard curve consisting of 108–101 copies of genomic HCMV
DNA. In all experiments the R2 value of the standard curve
exceeded 0.98. The results were normalized to the abundance of
GAPDH in the sample to correct for variations in loading.
To measure the nuclear export of viral mRNAs, RNA was
extracted from the nuclear and cytoplasmic fractions of infected
cells as described above. The abundance of each transcript in the
nuclear and cytoplasmic fractions was determined by qRT-PCR
using a standard curve, and normalized to the abundance of the
transcript in total RNA isolated from an aliquot of the sample prior
to fractionation. The nuclear to cytoplasmic ratio for each mRNA in
control cells expressing scrambled shRNA was set to one.
To measure protein abundance cells were collected by scraping
and frozen as dry pellets at 80 °C until use. Cells were lysed in
RIPA buffer (50 mM Tris–HCl: 50 mM, pH 7.4, 150 mM NaCl, 1% NP-
40: 1%, 0.25% deoxycholate, 1 mM EDTA) and the protein con-
centration determined by the Bradford assay. Equivalent amounts
of protein were resolved on SDS-PAGE gels and transferred to
nitrocellulose membranes (Amersham). For monoclonal anti-
bodies membranes were blocked for one hour at room tempera-
ture in 5% milk in TBS-T (50 mM Tris, 150 mM NaCl, 0.05% Tween
20) before incubation with primary antibody in TBST-T with 1%
BSA for one hour at room temperature or overnight at 4 °C. For
polyclonal antibodies, membranes were blocked in 5% milk fol-
lowed by incubation with primary antibody overnight at 4 °C in 5%
BSA in TBS-T. Antibodies to the following proteins were used in
this study: IE1 (Zhu et al., 1995; 1:10,000), UL44 (Virusys; 1:1000),
pp28 (Silva et al., 2003; 1: 5000), eIF4AIII (Bethyl A302-980A),
tubulin (Sigma 1:50,000), lamin A/C (Abcam 1:1000).Acknowledgments
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